The dramatic effectiveness of recent mRNA (mRNA)-based COVID vaccines delivered in lipid nanoparticles has highlighted the promise of mRNA therapeutics in general. In this report, we extend our earlier work on self-amplifying mRNAs delivered in spherical reconstituted virus-like particles (VLPs), and on drug delivery using cylindrical virus particles. In particular, we carry out separate assemblies of a self-amplifying mRNA gene in two different virus-like particles: one spherical, formed with the capsid protein of cowpea chlorotic mottle virus (CCMV), and the other cylindrical, formed from the capsid protein of tobacco mosaic virus (TMV). The mRNA gene is rendered self-amplifying by genetically fusing it to the RNA-dependent RNA polymerase (RdRp) of Nodamura virus, and the relative efficacies of cell uptake and downstream protein expression resulting from their CCMV- and TMV-packaged forms are compared directly. This comparison is carried out by their transfections into cells in culture: expressions of two self-amplifying genes, enhanced yellow fluorescent protein (EYFP) and Renilla luciferase (Luc), packaged alternately in CCMV and TMV VLPs, are quantified by fluorescence and chemiluminescence levels, respectively, and relative numbers of the delivered mRNAs are measured by quantitative real-time PCR. The cellular uptake of both forms of these VLPs is further confirmed by confocal microscopy of transfected cells. Finally, VLP-mediated delivery of the self-amplifying-mRNA in mice following footpad injection is shown by fluorescence imaging to result in robust expression of EYFP in the draining lymph nodes, suggesting the potential of these plant virus-like particles as a promising mRNA gene and vaccine delivery modality. These results establish that both CCMV and TMV VLPs can deliver their packaged mRNA genes to immune cells and that their self-amplifying forms significantly enhance expression. Choice of one VLP (CCMV or TMV) over the other will depend on which geometry of nucleocapsid is self-assembled more efficiently for a given length and sequence of RNA, and suggests that these plant VLP gene delivery systems will prove useful in a wide variety of medical applications, both preventive and therapeutic.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11250921PMC
http://dx.doi.org/10.1021/acs.molpharmaceut.3c01105DOI Listing

Publication Analysis

Top Keywords

virus-like particles
16
mrna gene
12
ccmv tmv
12
reconstituted virus-like
8
self-amplifying mrna
8
formed capsid
8
capsid protein
8
tmv vlps
8
mrna
7
self-amplifying
6

Similar Publications

Next-generation vaccines for influenza B virus: advancements and challenges.

Arch Virol

January 2025

CAS Key Laboratory of Molecular Virology & Immunology, Institutional Center for Shared Technologies and Facilities, Pathogen Discovery and Big Data Platform, Shanghai Institute of Immunity and Infection, Chinese Academy of Sciences, Yueyang Road 320, Shanghai, 200031, China.

To battle seasonal outbreaks of influenza B virus infection, which continue to pose a major threat to world health, new and improved vaccines are urgently needed. In this article, we discuss the current state of next-generation influenza B vaccine development, including both advancements and challenges. This review covers the shortcomings of existing influenza vaccines and stresses the need for more-effective and broadly protective vaccines and more-easily scalable manufacturing processes.

View Article and Find Full Text PDF

Effect of trypsin digestion on the integrity and antigenic epitopes of GII.6 norovirus virus-like particles.

Arch Virol

January 2025

Center for Translational Medicine, Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, The Sixth People's Hospital of Zhengzhou), Zhengzhou, 450000, People's Republic of China.

Trypsin digestion of the GII.6 norovirus (NoV) major capsid protein VP1 promotes its binding to histo-blood group antigens (HBGAs), which are believed to be co-receptors for NoVs. In our previous study, we found that trypsin digestion led to the disassembly of GII.

View Article and Find Full Text PDF

Advancements in nanoparticle-based vaccine development against Japanese encephalitis virus: a systematic review.

Front Immunol

January 2025

State Key Laboratory for Animal Disease Control and Prevention, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou, China.

Vaccination remains the sole effective strategy for combating Japanese encephalitis (JE). Both inactivated and live attenuated vaccines exhibit robust immunogenicity. However, the production of these conventional vaccine modalities necessitates extensive cultivation of the pathogen, incurring substantial costs and presenting significant biosafety risks.

View Article and Find Full Text PDF

An effectively protective VLP vaccine candidate for both genotypes of feline calicivirus.

Front Immunol

January 2025

State Key Laboratory for Animal Disease Control and Prevention, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, China.

Feline calicivirus (FCV) is one of the most widespread pathogens affecting feline animals. Currently, FCV is believed to be divisible into two genotypes, with prevalent strains encompassing both GI and GII. Vaccination is the primary means of preventing FCV infection, yet traditional inactivated or attenuated vaccines theoretically pose potential safety concerns.

View Article and Find Full Text PDF

H and B Blood Antigens Are Essential for In Vitro Replication of GII.2 Human Norovirus.

Open Forum Infect Dis

January 2025

Department of Microbiology and Immunology, School of Pharmaceutical Sciences, Wakayama Medical University, Wakayama, Japan.

Background: Human norovirus (HuNoV) is a major cause of enteric infectious gastroenteritis and is classified into several genotypes based on its capsid protein amino acid sequence and nucleotide sequence of the polymerase gene. Among these, GII.4 is the major genotype worldwide.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!